Rituximab, a lower-cost treatment, may be as effective at managing RRMS as the approved therapy Ocrevus, a new study from ...

The ENHANCE Phase 3b clinical trial is evaluating the safety and efficacy of a modified treatment regimen of Briumvi for ...

Roche has said it plans to UK price its latest multiple sclerosis drug Ocrevus in line with its close rival from Novartis - aiming to undercut some established rivals. Approved in Europe earlier ...

A subcutaneous (SC) injection version of Roche’s big-selling multiple sclerosis therapy Ocrevus has matched the current intravenous form in a clinical trial and, according to the company ...

2025 Healthcare & Pharmaceuticalscategory Roche fails in bid to increase dose of MS drug Ocrevus April 2, 2025 Healthcare & Pharmaceuticalscategory US Supreme Court largely backs FDA's denial of ...

Ocrevus (ocrelizumab) for multiple sclerosis; N6LS and cabotegravir to treat HIV; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; Epinephrine Injection to treat allergic ...

TG Therapeutics' Briumvi has shown strong revenue growth, with $310 million in FY24, and is expected to reach $540 million in ...

The European Commission approves RHHBY's Columvi combo to treat adult patients with diffuse large B-cell lymphoma after initial therapy.

Global drugmakers' stocks dropped across the board after U.S. President Donald Trump reiterated plans for a "major" tariff on pharmaceutical imports, threatening an interwoven global supply chain ...

As of April 16 at 4:00:00 PM EDT. Market Open.